兰瑞肽治疗2/3期常染色体显性多囊肾病三年随机双盲安慰剂对照研究
该随机双盲安慰剂对照试验纳入144例2/3期ADPKD成人,比较兰瑞肽120mg与安慰剂每月注射三年的疗效。主要终点mGFR斜率组间差异为-0.3 ml/min/1.73m2/年(95%CI -3.4至2.8),未达统计学意义,提示兰瑞肽未减缓mGFR下降。肌酐eGFR信号为探索性且未被胱抑素C或尿肌酐清除率重复,低血糖信号需关注。
要点
- 兰瑞肽未显著减缓2/3期ADPKD患者mGFR年下降斜率。
- 肌酐eGFR信号为探索性,未被胱抑素C或尿肌酐清除率支持。
- 兰瑞肽组低血糖发生率11.1%,高于安慰剂组1.4%,需监测。
核心结论
- 兰瑞肽未减缓2/3期ADPKD成人mGFR下降。
研究设计与样本
- 随机双盲安慰剂对照试验,计划180例,实际入组144例,意向性分析。
- 受试者为ADPKD成人,mGFR 30-89 ml/min/1.73m2。
- 干预为每月注射兰瑞肽120mg或0.9%氯化钠安慰剂,持续三年。
主要发现
- 主要终点未达到:mGFR轨迹年化组间差异-0.3 ml/min/1.73m2/年(95%CI -3.4至2.8)。
- 预设肌酐eGFR线性混合效应模型的时间×兰瑞肽系数显著+1.2 ml/min/1.73m2/年(0.27至2.15)。
- 肾脏事件率和生活质量评分组间相似。
- 胃肠道不良事件兰瑞肽组更频繁。
- 低血糖发生率为兰瑞肽组11.1% vs 安慰剂组1.4%。
临床怎么用
- 不推荐用兰瑞肽延缓2/3期ADPKD患者mGFR下降。
- 若考虑使用兰瑞肽,需主动监测低血糖。
- 肌酐eGFR变化不应作为兰瑞肽肾脏获益的独立依据。
局限性
- 因入组缓慢提前终止,实际样本量144例低于计划的180例。
- 肌酐eGFR信号为探索性,未被肌肉质量非依赖标志物重复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Somatostatin analogues reduce liver and kidney cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but randomized trials have not demonstrated a consistent benefit on kidney function decline. We tested whether the analogue lanreotide slows glomerular filtration rate (GFR) decline over three years in adults with ADPKD stages 2/3. METHODS: In this randomized, double-blind, placebo-controlled trial, we enrolled adults with ADPKD and measured GFR (mGFR) 30-89 ml/min/1.73 m2. Patients were randomized to receive monthly injections of lanreotide 120 mg or 0.9% sodium chloride placebo for three years. The primary endpoint was mGFR slope (iohexol clearance) assessed at baseline, weeks 72 and 144 and analyzed with a linear mixed-effects model (LMM). Secondary endpoints included annual estimated GFR decline (creatinine-based, assessed at 11 scheduled visits), kidney events, quality of life, and safety. Due to slow enrollment, recruitment stopped after 144 of 180 planned participants. All randomized participants were included in the analysis (intention-to-treat). RESULTS: The primary endpoint was not met: the model-derived annualized between-arm difference in mGFR trajectory was -0.3 ml/min/1.73 m2 per year (95% confidence interval -3.4 to 2.8). The time × lanreotide coefficient from the pre-specified creatinine-eGFR LMM was significant +1.2 ml/min/1.73 m2 per year (0.27 to 2.15); however, this signal was not replicated by cystatin C-eGFR nor urinary creatinine clearance, consistent with a non-GFR effect on creatinine physiology. Rates of kidney events and quality-of-life scores were similar between arms. Gastrointestinal adverse events were more frequent with lanreotide. Hypoglycemia occurred in 11.1% of lanreotide-treated versus 1.4% of placebo-treated participants. CONCLUSIONS: Lanreotide did not slow mGFR decline in adults with stage 2/3 ADPKD. The creatinine-eGFR signal is exploratory, not supported by muscle-mass-independent markers, and should be interpreted in the context of a negative primary endpoint. An unexpected hypoglycemia signal warrants proactive monitoring when considering lanreotide in this population. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02127437.
引用
- Joly D, Ursino M, Bienaimé F, et al. A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease. Kidney Int. 2026. PMID: 42320793. doi:10.1016/j.kint.2026.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。